home.social

#solidtumors — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #solidtumors, aggregated by home.social.

  1. Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases | Military Medical Research

    Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation…
    #NewsBeep #News #Health #atherosclerosis #AU #Australia #chronicinflammation #Clonalhematopoiesisofindeterminatepotential(CHIP) #Emergencymedicine #infection #solidtumors
    newsbeep.com/au/212505/

  2. Gilead bets on Xilio cancer drug as biotech restructures—Sanders blasts Novo Nordisk for ‘outrageous’ price of Ozempic, Wegovy—Boundless Bio breaks IPO lull with $100M fundraise--bit.ly/w28kSd #gileadsciences #solidtumors #berniesanders #drugpricing #novonordisk #ozempic #wegovy #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  3. AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him —Medtronic lifts annual profit forecast, exits ventilator business—FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor--bit.ly/w28kSd #abbvie #ceos #medtech #medtronic #earnings #ventilators #solidtumors #fda #tcelltherapy #iovance #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  4. AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him —Medtronic lifts annual profit forecast, exits ventilator business—FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor--bit.ly/w28kSd #abbvie #ceos #medtech #medtronic #earnings #ventilators #solidtumors #fda #tcelltherapy #iovance #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  5. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons

  6. Two important papers on #talazoparib and #avelumab in #solidtumors. Take home messsage: BRCA is associated with most responses and no clear advantage of combo over monotherapy with a caveat of being careful about cross-trial comparisons